OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. 

Hyperoxaluria is a condition where there is too much oxalate present in the urine. It can be caused by inherited (genetic) disorders, an intestinal disease or eating too many oxalate-rich foods. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes. Oxabact® holds Orphan Drug designations in Europe and in the US for the treatment of primary hyperoxaluria.